Table 1.
Summary of case studies.
Fig 1.
3D geometry of the human eye with anatomical regions and boundary conditions (B.C) (a) Partially liquefied (PL) VH and (b) VH without PL.
Fig 2.
Vitreous concentration–time profiles for ranibizumab under four studies, compared with computational data from Zhang et al. (2018) [20].
Table 2.
Calculated ranibizumab vitreous half-lives in days.
Table 3.
Predicted intravitreal half-life of ranibizumab for different intravitreal injection locations.
Fig 3.
Drug concentration in the human macula and VEGF-suppression threshold.
Fig 4.
Pressure distribution and Darcy flow streamlines in the vitreous humor.
The liquefied region is a sphere for (a) radius mm located at
mm, (b) radius
mm located at
mm, and (c) radius
mm located at
mm.
Fig 5.
Sensitivity of drug concentration to diffusion coefficient () (a) Drug concentration-time profile in vitreous humor (b) Drug concentration-time profile in macula using domain vs point probe.
Fig 6.
Sensitivity of drug concentration for varying hydraulic conductivity (K) values (a) Drug concentration-time profile in vitreous humor(VH) (b) Drug concentration-time profile in macula using domain vs point probe.